Want to see HK:1513 full AI Analyst Report?
Top Page
Livzon Pharmaceutical Group
(1513)
Select Model
Select Model
Rating:72Outperform
Price Target:
HK$27.00
▼(-12.73% Downside)
Action:Reiterated
Date:04/24/26
The score is driven primarily by strong financial quality (healthy margins, conservative leverage, solid free cash flow) and supportive valuation with a high dividend yield. These positives are tempered by weak-to-neutral technical positioning (below longer-term moving averages) and ongoing revenue decline, which remains the key fundamental risk.
Positive Factors
High and stable margins
Sustained high gross and operating margins indicate durable pricing power and efficient manufacturing. These margin levels support consistent earnings, fund R&D and commercial efforts, and provide a buffer against pricing or input-cost shocks over the next 2–6 months.
Negative Factors
Multi-year revenue decline
A prolonged top-line decline erodes scale economies and limits revenue-driven margin expansion. Without identifiable structural growth drivers, stagnating sales create pressure on long-term growth, R&D ROI, and the ability to expand market share.
Read all positive and negative factors
Positive Factors
Negative Factors
High and stable margins
Sustained high gross and operating margins indicate durable pricing power and efficient manufacturing. These margin levels support consistent earnings, fund R&D and commercial efforts, and provide a buffer against pricing or input-cost shocks over the next 2–6 months.
Read all positive factors
Livzon Pharmaceutical Group (1513) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$26.80B
Dividend Yield4.09%
Average Volume (3M)553.85K
Price to Earnings (P/E)13.0
Beta (1Y)0.76
Revenue Growth1.48%
EPS Growth-1.55%
CountryHK
Employees9,067
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)2.21
Shares Outstanding299,807,130
10 Day Avg. Volume697,200
30 Day Avg. Volume553,853
Financial Highlights & Ratios
PEG Ratio8.43
Price to Book (P/B)1.65
Price to Sales (P/S)1.90
P/FCF Ratio9.02
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$39.00Price Target Upside26.05% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)2.36
Revenue Forecast (FY)HK$12.23B
Livzon Pharmaceutical Group Business Overview & Revenue Model
Company Description
Livzon Pharmaceutical Group Inc., founded in Zhuhai, China, in 1985, is a prominent enterprise dedicated to the research, development, manufacturing, and global commercialization of a wide range of pharmaceutical products, including finished drugs...
How the Company Makes Money
null...
Livzon Pharmaceutical Group Financial Statement Overview
Summary
Income Statement
77
Positive
Balance Sheet
82
Very Positive
Cash Flow
74
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 11.67B | 12.02B | 11.81B | 12.43B | 12.63B | 12.06B |
| Gross Profit | 7.67B | 7.92B | 7.73B | 7.66B | 8.17B | 7.81B |
| EBITDA | 3.04B | 3.10B | 3.47B | 3.33B | 3.08B | 2.77B |
| Net Income | 1.96B | 2.02B | 2.06B | 1.95B | 1.91B | 1.78B |
Balance Sheet | ||||||
| Total Assets | 24.11B | 24.00B | 24.46B | 25.04B | 24.86B | 22.37B |
| Cash, Cash Equivalents and Short-Term Investments | 9.56B | 10.93B | 10.92B | 11.41B | 10.52B | 9.33B |
| Total Debt | 2.89B | 3.85B | 3.93B | 3.48B | 3.62B | 2.69B |
| Total Liabilities | 8.58B | 8.20B | 9.55B | 10.28B | 9.93B | 8.06B |
| Stockholders Equity | 14.46B | 13.89B | 13.86B | 14.04B | 13.88B | 13.00B |
Cash Flow | ||||||
| Free Cash Flow | 2.75B | 2.54B | 2.41B | 2.43B | 1.83B | 593.23M |
| Operating Cash Flow | 3.28B | 3.10B | 2.98B | 3.25B | 2.77B | 1.90B |
| Investing Cash Flow | -4.36B | -3.67B | -660.33M | -708.37M | -1.23B | -1.88B |
| Financing Cash Flow | -2.65B | -2.62B | -2.49B | -1.66B | -720.36M | -815.02M |
Livzon Pharmaceutical Group Technical Analysis
Negative
30.94
Price Trends
25.35
Negative
26.07
Negative
28.08
Negative
Market Momentum
-0.45
Positive
34.35
Neutral
9.13
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1513, the sentiment is Negative. The current price of 30.94 is above the 20-day moving average (MA) of 24.45, above the 50-day MA of 25.35, and above the 200-day MA of 28.08, indicating a bearish trend. The MACD of -0.45 indicates Positive momentum. The RSI at 34.35 is Neutral, neither overbought nor oversold. The STOCH value of 9.13 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1513.
Livzon Pharmaceutical Group Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | HK$26.80B | 13.01 | 13.95% | 4.09% | 1.48% | -1.55% | |
63 Neutral | HK$25.08B | 14.57 | 8.65% | 2.26% | 10.00% | -7.54% | |
61 Neutral | HK$16.63B | 6.40 | 12.65% | 5.11% | -4.09% | -22.73% | |
58 Neutral | HK$26.64B | 5.97 | 7.98% | 2.95% | 4.66% | 20.76% | |
57 Neutral | HK$16.68B | 13.41 | 7.26% | 3.13% | 5.48% | -49.67% | |
56 Neutral | HK$35.69B | 11.01 | 7.70% | 7.15% | 7.32% | 12.84% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
HK:1513
Livzon Pharmaceutical Group
23.88
-3.85
-13.87%
HK:3933
The United Laboratories International Holdings
8.43
-5.98
-41.52%
HK:0867
China Medical System Holdings
10.28
-1.42
-12.17%
HK:0874
Guangzhou Baiyunshan Pharmaceutical Holdings Company
14.21
-2.20
-13.43%
HK:3320
China Resources Pharmaceutical Group Ltd.
4.24
-0.65
-13.27%
HK:0512
Grand Pharmaceutical Group Limited
4.70
-3.73
-44.23%
Livzon Pharmaceutical Group Corporate Events
Livzon Subsidiary’s Ankylosing Spondylitis Drug Application Accepted by China’s NMPA
Jun 1, 2026
Livzon MABPharm, a subsidiary of Livzon Pharmaceutical Group, has had its marketing authorization application for Lecankitug Injection formally accepted for review by China’s National Medical Products Administration. The domestically develop...
Livzon Wins NMPA Approval for Biosimilar Fertility Drug
Jun 1, 2026
Livzon MAB Pharm, a subsidiary of Livzon Pharmaceutical Group, has obtained a drug registration certificate from China’s National Medical Products Administration for its independently developed Recombinant Human Follitropin Alfa Solution for...
Livzon Pharmaceutical Wins Shareholder Backing for All 2025 AGM and 2026 Class Meeting Resolutions
May 29, 2026
Livzon Pharmaceutical Group reported that its 2025 annual general meeting and the first 2026 class meetings for A and H shareholders were held on 29 May 2026 in Zhuhai, Guangdong, with all resolutions duly approved by poll. The company detailed th...
Livzon Pharmaceutical Revamps Board and Affirms Director Independence
May 29, 2026
Livzon Pharmaceutical Group has completed a broad refresh of its twelfth-session board, with shareholders approving the re-election of several non-executive directors and independent non-executive directors, while confirming a consistent remunerat...
Livzon Pharmaceutical Outlines Board and Committee Structure in Governance Update
May 29, 2026
Livzon Pharmaceutical Group has detailed the current composition of its board of directors, listing executive, non-executive, independent and employee representative members and their respective leadership roles. The announcement also clarifies wh...
Livzon Pharmaceutical Declares Final 2025 Dividend and Sets Hong Kong Payout Details
May 29, 2026
Livzon Pharmaceutical Group Inc. has declared a final ordinary cash dividend of RMB 14.3 per 10 shares for the financial year ended 31 December 2025, with shareholders approving the payout on 29 May 2026. The dividend will be paid to Hong Kong sha...
Livzon Secures Controlling Stake in Vietnam’s Imexpharm After Tender Offer Completion
May 11, 2026
Livzon Pharmaceutical Group has completed a voluntary public tender offer for shares in Vietnam’s Imexpharm Corporation through its subsidiary LIANSGP Holding Pte. Ltd., after the offer period closed on 29 April 2026. Shareholders of Imexpha...
Livzon Gains Control of Vietnam’s Imexpharm in RMB 1.56 Billion Tender Offer
Apr 29, 2026
Livzon Pharmaceutical Group has disclosed the outcome of a voluntary public tender offer, conducted via its subsidiary LIANSGP Holding Pte. Ltd., for shares in Vietnam-listed Imexpharm Corporation. Following the close of the offer period, LIANSGP ...
Livzon Pharmaceutical Clarifies Independence of Key Board Directors
Apr 28, 2026
Livzon Pharmaceutical Group has issued a supplemental announcement clarifying the independence of four independent non-executive directors, Mr. Luo Huiyuan, Ms. Cui Lijie, Ms. Wang Zhiyao and Ms. Kang Li, in line with Hong Kong Listing Rules. Each...
Livzon Pharmaceutical Issues Revised Proxy Form for 2025 AGM
Apr 24, 2026
Livzon Pharmaceutical Group has issued a revised proxy form for its 2025 annual general meeting scheduled for 29 May 2026, replacing the original version solely to correct typographical and formatting issues without altering any substantive conten...
Livzon Pharmaceutical Updates 2025 Final Dividend Timetable and Tax Details
Apr 23, 2026
Livzon Pharmaceutical Group has updated details of its proposed final dividend for the financial year ended 31 December 2025, declaring a cash payout of RMB 14.3 per 10 shares subject to shareholder approval on 29 May 2026. The company clarified t...
Livzon Pharmaceutical Sets 2025 AGM to Approve Results and Cash Dividend Plan
Apr 23, 2026
Livzon Pharmaceutical Group has called its 2025 annual general meeting for 29 May 2026 in Zhuhai, combining on-site and online voting for shareholders. The agenda covers approval of the 2025 annual report, board work report and financial accounts,...
Livzon Seeks Mandate for 10% H-Share Buyback to Bolster Capital Flexibility
Apr 23, 2026
Livzon Pharmaceutical Group has convened its first 2026 class meeting of H shareholders to vote on a special resolution granting the board a general mandate to repurchase up to 10% of the company’s H shares. The proposed authorization would ...
Livzon Pharmaceutical’s First-Quarter Profit Slips as Policy Shift and Seasonality Hit Revenue
Apr 23, 2026
Livzon Pharmaceutical Group reported unaudited first-quarter 2026 results prepared under China Accounting Standards, showing operating income of RMB2.871 billion and net profit attributable to shareholders of RMB577 million. Operating income and n...
Livzon Reshapes Board Succession Plan With Nomination of Vice President Liu Daping
Apr 23, 2026
Livzon Pharmaceutical Group has adjusted its board succession plan by withdrawing an earlier proposal to appoint Vice President Liu Daping as an executive director in the 11th board session, instead nominating him for the 12th board session to ali...
Livzon Wins NMPA Nod for JP-1366 H. pylori Trial, Deepening GI Drug Portfolio
Apr 10, 2026
Livzon Pharmaceutical Group has received approval from China’s National Medical Products Administration to conduct clinical trials of its innovative JP-1366 tablet, a potassium-competitive acid blocker, in combination with antibiotics for th...
Livzon Pharmaceutical Schedules Board Meeting to Review First-Quarter 2026 Results
Apr 8, 2026
Livzon Pharmaceutical Group has scheduled a board meeting for 23 April 2026 to review and approve the unaudited quarterly results for the three months ended 31 March 2026, and to address any other business matters. The announcement underlines regu...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.